• ICR welcomes new advanced prostate cancer treatment guideline pharmatimes
    May 08, 2020
    The Institute of Cancer Research, London, has welcomed approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.
  • FDA Approves Generic Abiraterone americanpharmaceuticalreview
    July 16, 2019
PharmaSources Customer Service